Dentsply Sirona announces changes to management team

John Groetelaars, the new interim CEO of Dentsply Sirona

Dentsply Sirona has announced the appointment of John Groetelaars as the interim CEO, while the company searches for the next CEO has retained a leading executive search firm to support the process.

He has succeeded Don Casey, who has been terminated as CEO and will cease to serve as a member of the board with immediate effect.

Eric Brandt, non-executive chairman of the board stated: “We are pleased to welcome John as Dentsply Sirona’s interim CEO. John has a strong track record of driving innovative business strategies, and as a seasoned executive with more than 30 years of industry experience, he is uniquely positioned to lead our company during this transition period.”

Groetelaars commented: “I look forward to serving as Interim CEO during this important time for the Company. I joined the company’s board because of my deep appreciation for our mission and unwavering commitment to innovation, operational excellence and providing positive outcomes for patients and customers.

“The board is confident that renewing the company’s focus on execution will stabilise the business and deliver strong performance despite ongoing macroeconomic challenges. This will be my focus from day one, and I am prepared to leverage my prior executive leadership experience as I work with the rest of the board and management team to drive the company’s strategy and advance its vision to transform dentistry and improve oral health globally.”

Barbara Bodem, interim CFO of Dentsply Sirona

Dentsply Sirona has also appointed Barbara Bodem as the interim CFO, effective upon Jorge Gomez’s previously announced departure on 6 May 2022. Bodem will join the company on 25 April 2022 and work closely with Gomez to ensure a seamless transition.

Bodem has over two decades of financial leadership experience in the healthcare industry, most recently serving as senior vice-president and CFO of Hillrom. Previously, Barbara served in senior leadership roles at Mallinckrodt Pharmaceuticals, Hospira and Eli Lilly and Company.

Brandt commented: “We are fortunate to welcome Barbara, a proven finance executive, as our interim CFO during this transition period. Barbara brings extensive expertise in healthcare with an international perspective, having served in multiple leadership roles across finance organisations at global companies. As we continue our search for a permanent CFO, we believe that Barbara and our talented financial team will continue to deliver value for our patients, business partners and shareholders.”